CapitaLandInvest
9CI
UOB
U11
OCBC Bank
O39
ST Engineering
S63
JMH USD
J36
(FY)Dec 31, 2024 | (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | (Q4)Dec 31, 2019 | (Q3)Sep 30, 2019 | (Q2)Jun 30, 2019 | (Q1)Mar 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -0.22%15.97T | -10.08%16T | -9.47%17.8T | 35.81%19.66T | 6.04%14.47T | -2.91%13.65T | -6.36%3.56T | -3.05%3.59T | -6.62%3.14T | 5.28%3.36T |
Cost of revenue | -11.93%11.2T | -3.91%12.72T | -9.24%13.24T | 26.22%14.59T | -0.59%11.56T | -2.00%11.62T | -18.05%2.76T | -3.13%3T | 3.95%2.97T | 13.92%2.9T |
Gross profit | 45.19%4.76T | -28.01%3.28T | -10.13%4.56T | 73.80%5.07T | 44.08%2.92T | -7.84%2.03T | 84.35%798.62B | -2.68%595.92B | -66.38%170.11B | -28.68%460.97B |
Operating expense | 22.33%1.65T | -20.08%1.35T | -7.54%1.69T | 42.36%1.83T | -9.23%1.28T | -3.83%1.41T | -32.38%261.4B | 19.48%453.58B | 10.87%386.84B | -12.13%312.21B |
Selling and administrative expenses | -3.18%1.2T | -1.63%1.24T | -21.96%1.26T | 31.39%1.62T | -16.45%1.23T | 4.61%1.47T | 3.88%354.76B | 3.18%401.6B | 8.31%379.83B | 3.11%338.37B |
-Selling and marketing expense | -6.44%456.8B | -0.92%488.23B | -42.23%492.76B | 71.30%852.94B | -3.59%497.92B | -1.63%516.47B | -4.29%126.75B | -9.93%135.69B | 16.60%143.48B | -7.00%110.56B |
-General and administrative expense | -1.07%746.39B | -2.08%754.44B | 0.61%770.45B | 4.33%765.79B | -23.38%734.03B | 8.31%958.07B | 9.05%228B | 11.46%265.91B | 3.82%236.35B | 8.85%227.81B |
Other operating expenses | 154.80%1.02T | -29.47%399.07B | 34.35%565.81B | 241.28%421.16B | -38.20%123.41B | 78.50%199.7B | -28.11%25.27B | 352.58%113.81B | 99.51%37.92B | -48.64%22.7B |
Total other operating income | 94.91%568.29B | 108.69%291.57B | -34.34%139.71B | 195.87%212.79B | -72.36%71.92B | 409.25%260.23B | 1,300.31%118.63B | 77.88%61.82B | 48.65%30.91B | 186.36%48.87B |
Operating profit | 61.17%3.11T | -32.68%1.93T | -11.59%2.87T | 98.48%3.25T | 167.36%1.64T | -15.94%611.6B | 1,051.32%537.22B | -38.84%142.34B | -237.95%-216.72B | -48.89%148.76B |
Net non-operating interest income expense | 28.66%-300.3B | 13.09%-420.97B | 13.52%-484.37B | 16.81%-560.12B | 12.65%-673.31B | -25.18%-770.84B | -10.38%-189.97B | -17.47%-196.46B | -36.00%-199.45B | -42.54%-184.96B |
Non-operating interest income | 35.34%241.39B | 86.72%178.36B | 36.38%95.52B | -1.37%70.04B | -16.71%71.01B | -18.18%85.26B | -42.61%15.36B | -7.46%20.82B | -10.54%23.79B | -10.77%25.29B |
Non-operating interest expense | -9.62%541.69B | 4.99%599.33B | -8.14%570.83B | -15.19%621.42B | -12.98%732.73B | 20.11%842.03B | 6.29%191.27B | 14.51%217.28B | 28.86%223.24B | 32.99%210.25B |
Total other finance cost | ---- | ---- | 3.57%9.06B | -24.51%8.75B | -17.61%11.59B | -25.68%14.06B | ---- | ---- | ---- | ---- |
Net investment income | 4,490.14%73.01B | -102.50%-1.66B | 2,981.27%66.62B | 94.83%-2.31B | -494.91%-44.71B | 109.59%11.32B | -31.65%13.62B | 76.02%-9.43B | 104.25%3.28B | 117.92%3.86B |
Gain/Loss on financial instruments designated as cash flow hedges | ||||||||||
Gain/Loss on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | 192.95%52.41B | 68.02%17.89B | -75.44%10.65B | 135.35%43.36B | -138.79%-122.65B | 22.34%-51.36B | 104.95%6.47B | -86.54%5.71B | -150.99%-15.61B | -456.50%-47.93B |
Special income /charges | 46.61%-250B | -8,220.22%-468.21B | 108.34%5.77B | -422.78%-69.13B | ||||||
Less:Impairment of capital assets | ---- | ---- | -64.80%173.56B | 18,599.51%493.11B | -94.78%2.64B | 13,861.33%50.54B | ---- | ---- | ---- | ---- |
Less:Other special charges | ---- | ---- | -102.32%-50.37B | -196.25%-24.89B | 45.08%-8.4B | 31.39%-15.3B | ---- | ---- | ---- | ---- |
Less:Write off | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---- | ---- |
Less:Negative goodwill immediately recognized | ---- | ---- | --126.8B | --0 | ---- | 6,417.31%33.89B | ---- | ---- | ---- | ---- |
Other non-operating income /expenses | -31.11%5.61B | 37.56%8.15B | 18.69%5.92B | 9.76%4.99B | ||||||
Income before tax | 92.43%2.94T | -31.16%1.53T | -2.14%2.22T | 181.12%2.27T | 406.04%806.18B | -467.56%-263.42B | 244.30%303.2B | -184.33%-57.84B | -1,088.57%-428.51B | -161.20%-80.27B |
Income tax | 40.22%828.21B | -34.38%590.66B | -8.13%900.15B | 52.47%979.79B | 43.99%642.62B | 17.41%446.29B | 97.33%299.46B | 52.70%132.63B | -156.98%-35.82B | -36.38%50.03B |
Net income | 125.38%2.11T | -28.95%936.22B | 2.43%1.32T | 686.55%1.29T | 123.05%163.57B | -66.40%-709.72B | 101.03%3.73B | -942.80%-190.47B | -296.98%-392.68B | -348.01%-130.3B |
Net income continuous operations | 125.38%2.11T | -28.95%936.22B | 2.43%1.32T | 686.55%1.29T | 123.05%163.57B | -66.40%-709.72B | 101.03%3.73B | -942.80%-190.47B | -296.98%-392.68B | -348.01%-130.3B |
Noncontrolling interests | 207.89%991.33B | -41.22%321.98B | 3.86%547.78B | 267.14%527.41B | 148.15%143.65B | -45.72%-298.36B | 110.04%15.08B | -139.93%-64.79B | -481.02%-176.15B | -2,747.24%-72.51B |
Net income attributable to the company | 82.12%1.12T | -20.23%614.24B | 1.43%769.98B | 3,712.22%759.13B | 104.84%19.91B | -85.49%-411.35B | 94.64%-11.35B | -1,538.11%-125.68B | -215.65%-216.54B | -216.05%-57.79B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 82.12%1.12T | -20.23%614.24B | 1.43%769.98B | 3,712.22%759.13B | 104.84%19.91B | -85.49%-411.35B | 94.64%-11.35B | -1,538.11%-125.68B | -215.65%-216.54B | -216.05%-57.79B |
Gross dividend payment | ||||||||||
Basic earnings per share | 82.05%801 | -20.29%440 | 1.47%552 | 3,785.71%544 | 104.75%14 | -85.53%-295 | 94.47%-8.4 | -1,528.57%-90 | -215.89%-155.1 | 73.95%-41.4 |
Diluted earnings per share | 82.05%801 | -20.29%440 | 1.47%552 | 3,785.71%544 | 104.75%14 | -85.53%-295 | 94.47%-8.4 | -1,528.57%-90 | -215.89%-155.1 | 73.95%-41.4 |
Dividend per share | 9.27%96.199 | 4.56%88.0352 | 84.1972 | 0 | 0 | -64.44%26.1053 | 0 | 0 | -64.44%26.1053 | 0 |
Currency Unit | IDR | IDR | IDR | IDR | IDR | IDR | IDR | IDR | IDR | IDR |